Gilead Sciences, Inc. $GILD Position Trimmed by BLI Banque de Luxembourg Investments

BLI Banque de Luxembourg Investments trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 76.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,531 shares of the biopharmaceutical company’s stock after selling 8,000 shares during the quarter. BLI Banque de Luxembourg Investments’ holdings in Gilead Sciences were worth $312,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after buying an additional 2,113,692 shares in the last quarter. Norges Bank purchased a new stake in Gilead Sciences during the fourth quarter valued at about $2,617,152,000. Invesco Ltd. lifted its stake in Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after buying an additional 1,618,453 shares in the last quarter. Legal & General Group Plc lifted its stake in Gilead Sciences by 1.0% during the fourth quarter. Legal & General Group Plc now owns 10,317,613 shares of the biopharmaceutical company’s stock valued at $1,266,384,000 after buying an additional 107,014 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Gilead Sciences by 5.9% during the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock valued at $793,506,000 after buying an additional 400,002 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive Phase 3 results for their once-weekly oral HIV regimen, islatravir/lenacapavir, meeting the primary efficacy endpoint in both ISLEND trials. This is important because it supports Gilead’s HIV franchise, which is a major driver of the company’s business. Article Title
• Positive Sentiment: Analysts and media coverage highlighted that the successful once-weekly HIV tablet could strengthen Gilead’s core growth outlook, since a more convenient regimen may help expand or defend market share in HIV treatment. Article Title
• Neutral Sentiment: Gilead and Merck also discontinued a Phase 3 lung cancer study of Trodelvy plus Keytruda after it failed to show a statistically significant progression-free survival benefit. The trial stop is disappointing, but it mainly affects Gilead’s oncology ambitions rather than its larger HIV business. Article Title
• Neutral Sentiment: RBC noted a potential longer-term competitive threat from in vivo CAR-T technology, but this looks more like an early-stage strategic risk than a near-term catalyst for the stock. Article Title
• Negative Sentiment: At least one report characterized the news as mixed because the HIV win was partially offset by the Trodelvy setback, which may temper investor enthusiasm for Gilead’s broader pipeline. Article Title

Analyst Upgrades and Downgrades

A number of research firms have commented on GILD. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Gilead Sciences in a research note on Tuesday. Citigroup raised their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Scotiabank raised their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Argus increased their target price on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Finally, Barclays started coverage on Gilead Sciences in a research report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 target price for the company. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at $81,185,357.82. This trade represents a 2.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This trade represents a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,000 shares of company stock valued at $9,047,570 in the last quarter. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Down 2.0%

Shares of Gilead Sciences stock opened at $125.50 on Wednesday. The stock has a 50-day moving average price of $134.03 and a 200 day moving average price of $134.37. The company has a market cap of $155.82 billion, a P/E ratio of 17.10 and a beta of 0.31. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.